CDK4/6 inhibition provides additional efficacy in HER2(+), HR(+) breast cancer. Killock D. Nat Rev Clin Oncol 2026 Feb 17. doi: 10.1038/s41571-026-01133.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Killock D. CDK4/6 inhibition provides additional efficacy in HER2(+), HR(+) breast cancer. Nat Rev Clin Oncol 2026 Feb 17. doi: 10.1038/s41571-026-01133.
PMID: 41703320